Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia

• Published in: Japanese journal of antibiotics Vol. 67; no. 1; p. 23
• Main Authors: Yamasaki, Kei, Yatera, Kazuhiro, Kawanami, Toshinori, Sasahara, Yosuke, Hata, Ryosuke, Uchimura, Keigo, Tachiwada, Takashi, Naito, Keisuke, Kato, Kaori, Takaki, Tsutomu, Shimabukuro, Ikuko, Shiraishi, Tomoko, Oda, Keishi, Hara, Kanako, Chojin, Yasuo, Suzuki, Yu, Akata, Kentarou, Ogoshi, Takaaki, Tokuyama, Susumu, Inoue, Naoyuki, Noguchi, Shingo, Nishida, Chinatsu, Orihashi, Takeshi, Yoshida, Yugo, Kawanami, Yukiko, Taura, Yuusuke, Ishimoto, Hiroshi, Obata, Hideto, Awaya, Yukikazu, Tsuda, Tohru, Yoshii, Chiharu, Mukae, Hiroshi
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-02-2014
• Subjects: Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Cross Infection; Female; Humans; Japan; Levofloxacin - adverse effects; Levofloxacin - therapeutic use; Male; Ofloxacin; Pneumonia - drug therapy; Prospective Studies
• ISSN: 0368-2781
• DOI: 10.11553/antibiotics.67.1_23

Levofloxacin (LVFX) is one of respiratory quinolones with wide spectrum of antimicrobial efficacy for Gram-positive and -negative bacteria and also atypical bacteria, and 500 mg of intravenous LVFX infusion has recently been able to use once daily based on pharmacokinetics-pharmacodynamics in Japan. So far, there had been no reports of the prospective studies evaluating efficacy and safety of LVFX in patients with nursing and healthcare-associated pneumonia (NHCAP). This study was conducted to evaluate prospectively the efficacy and safety of LVFX in patients with NHCAP categories B and C (other antibacterial agents were allowed to use with LVFX) according to Japanese guideline for NHCAP by the Japanese Respiratory Society (JRS). LVFX 500 mg was intravenously administered once daily, and the clinical efficacy and safety were evaluated by clinical symptoms, peripheral blood laboratory findings and chest X-rays. Sixty-two patients (average age was 81.2 years old, female/male was 22/40) were firstly registered and evaluated for the safety of LVFX, and eventually 54 patients were enrolled for the evaluation of clinical efficacy of LVFX. The percentage of these 54 patients aged over 65 years old was 96.3%, NHCAP category B/C was 33/21. The efficacy of LVFX in all 54 patients evaluated was 85.2% (categories B/C of NHCAP was 81.8/90.5%). In addition, the efficacies of LVFX in each pneumonia severity category by A-DROP system by JRS in NHCAP patients were 100% in mild, 86.7% in moderate, 77.8% in severe/very severe. Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX. All of the patients with liver and renal dysfunctions after starting LVFX administration demonstrated mild dysfunctions and continued LVFX treatment, and these dysfunctions normalized soon after cessation of LVFX. LVFX was changed to other antibacterial agent in one patient with thrombocytopenia, and also thrombocytopenia was normalized thereafter. In conclusion, LVFX is effective and relatively safe for categories B and C in patients with NHCAP.